On April 10, 2024, NeuroSense Therapeutics Ltd., a biotechnology company focused on neurodegenerative diseases, announced a securities purchase agreement with an institutional investor for a registered direct offering and concurrent private placement. The company agreed to issue 1,732,000 ordinary shares at $1.50 each and 1,248,000 pre-funded warrants at $1.4999 per warrant, aiming to raise approximately $4.47 million before fees and expenses. The pre-funded warrants, exercisable immediately at $0.0001 per share, prevent the purchaser from exceeding a 9.99% ownership post-transaction. Directors and executive officers will enter a 90-day lock-up agreement post-closing, and the company will not issue additional shares for 60 days, with certain exceptions. The offering includes 2,980,000 ordinary warrants, exercisable at $1.50 per share, expiring five years from issuance. These warrants and the shares issuable upon...Show More

On April 10, 2024, NeuroSense Therapeutics Ltd., a biotechnology company focused on neurodegenerative diseases, announced a securities purchase agreement with an institutional investor for a registered direct offering and concurrent private placement. The company agreed to issue 1,732,000 ordinary shares at $1.50 each and 1,248,000 pre-funded warrants at $1.4999 per warrant, aiming to raise approximately $4.47 million before fees and expenses. The pre-funded warrants, exercisable immediately at $0.0001 per share, prevent the purchaser from exceeding a 9.99% ownership post-transaction. Directors and executive officers will enter a 90-day lock-up agreement post-closing, and the company will not issue additional shares for 60 days, with certain exceptions. The offering includes 2,980,000 ordinary warrants, exercisable at $1.50 per share, expiring five years from issuance. These warrants and the shares issuable upon exercise are not registered under the Securities Act and are offered under an exemption. NeuroSense has committed to filing a registration statement for the resale of shares from the ordinary warrants within 60 days. A.G.P./Alliance Global Partners is the exclusive placement agent, receiving a 7% fee, partially payable in ordinary shares. The offering is expected to close on April 15, 2024, with proceeds intended for working capital and general corporate purposes. The offering is made under a registration statement on Form F-3, effective as of January 30, 2023, and a prospectus supplement dated April 10, 2024.